Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 411.8% in August

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 34,593 shares, an increase of 411.8% from the August 15th total of 6,759 shares. Based on an average trading volume of 31,550 shares, the days-to-cover ratio is currently 1.1 days. Approximately 2.4% of the company’s stock are sold short.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM traded up $0.25 during mid-day trading on Friday, hitting $62.22. 17,643 shares of the company’s stock were exchanged, compared to its average volume of 18,027. The company has a market cap of $90.84 million, a PE ratio of -26.59 and a beta of 1.19. Global X Genomics & Biotechnology ETF has a 52 week low of $36.13 and a 52 week high of $68.00. The company has a 50-day simple moving average of $59.49 and a 200 day simple moving average of $51.50.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently declared a semiannual dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 29th were paid a $0.0579 dividend. This represents a yield of 20.0%. The ex-dividend date was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is presently -27.35%.

Institutional Trading of Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Financial Designs Inc. ADV raised its stake in shares of Global X Genomics & Biotechnology ETF by 4.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after purchasing an additional 481 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after purchasing an additional 4,615 shares during the last quarter. Wealth Management Partners LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the 1st quarter worth about $244,000. Jane Street Group LLC boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 7.7% during the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after buying an additional 10,308 shares during the period. Finally, Sei Investments Co. grew its position in shares of Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares during the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.